Plus Therapeutics, Inc. (PSTV)


-0.03 (0.00%)
Symbol PSTV
Price $1.25
Beta 0.334
Volume Avg. 0.42M
Market Cap 3.600M
Shares () -
52 Week Range 1.18-10.95
1y Target Est -
DCF Unlevered PSTV DCF ->
DCF Levered PSTV LDCF ->
ROE -299.77% Strong Sell
ROA -122.40% Strong Sell
Operating Margin -
Debt / Equity 186.14% Buy
P/E -0.16 Neutral
P/B 1.18 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PSTV news

Dr. Marc H. Hedrick M.B.A., M.D.
NASDAQ Capital Market

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.